Trials / Unknown
UnknownNCT00994305
Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- Sponsor
- University of Sao Paulo General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigate the therapeutic effects of the antioxidant N-acetylcysteine on early outcomes of deceased renal transplant patients.
Detailed description
Investigate the therapeutic effects of 600 mg bid po of N-acetylcysteine on early outcomes of deceased renal transplant patients regarding oxidative stress and renal function. Adult primary graft recipients of deceased renal donors will be randomly assign to treatment (NAC) or control group and prospectively evaluated for 90 days. Treatment group will receive N-acetylcysteine 600 mg bid po from 0 to 7th postoperative day (PO). Renal function will be determined by serum creatinine, Cockroft-Gault estimated GFR (eGFR) at 7th, 15th, 30th, 60th and 90th PO and dialysis free Kaplan-Meier estimate curve. Serum levels of thiobarbituric acid reactive substances (TBARS), which are markers of lipid peroxidation and oxidative stress, will be determined using the thiobarbituric acid assay from 0-7th PO. Statistical analysis will be performed using SPSS 16.0.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-acetylcysteine | 600 mg bid po 0-7 PO |
| DRUG | control | No treatment: standard care provided. No N-acetylcysteine administration. |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2008-06-01
- Completion
- 2009-12-01
- First posted
- 2009-10-14
- Last updated
- 2009-10-14
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00994305. Inclusion in this directory is not an endorsement.